Tags : Celiac Disease


Takeda Acquires Exclusive Worldwide License Rights for COUR’s CNP-101 to

Shots: COUR to receive ~$420M milestone and royalties on sales of licensed products. Takeda exercised its option to acquire the exclusive global license to develop and commercialize TAK-101/CNP-101 following P-IIa proof-of-concept placebo-controlled study In Dec’2015, Takeda and COUR collaborated to develop therapies for celiac disease, provided Takeda an exclusive option to acquire a WW license […]Read More